The genetic risk factors, such as TP53 R249S mutant, TERT promoter mutations, and Wnt/B‐catenin pathway alterations, influence disease progression and treatment response in HCC subjects with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. The gene discussed is TP53; the disease is hepatocellular carcinoma.